Search

Heart failure (HF) is determined by pathophysiologic changes in the left ventricle (LV) that occur before the onset of clinical symptoms; these changes can lead to mitral insufficiency that will maintain and favor ventricular dysfunction. An associated change in contractility occurs which will maintain the vicious circle. 252 patients with HF were included in this cross-sectional analysis. Patients were divided into two groups, Group I-S/V (n = 55) and Group II-CT (n = 197) to comparatively assess cardi-ac parameters according to the administered therapy and to determine their correlation with quality of life domains. 2D measurements were performed to determine ultrasound parameters. The WHOQOL-BREF questionnaire was used to assess the quality of life. When analyzing the mean values of the determined echocardiographic parame-ters, significant differences in LV ejection fraction (LVEF) (p < 0.03) Results: Analysing the mean values of the echocardiographic parameters determined, significant differences in LV ejection fraction (LV ejection fraction (LVEF) (p < 0.001) and right ventricular diameter (p = 0.030) were found between the two study groups. The incidence of aortic regurgitation and tricuspid regurgitation was higher in the I-S/V group (40% vs. 25%, p = 0.001, respec-tively 47% vs. 35%, p = 0.03). Mitral regurgitation was present in relatively similar per-centages. Testing the association of echocardiographic parameters with quality of life do-mains showed a significant association of LVEF with physical health and relationship with the environment (p = 0.002, r = 0.143, respectively p = 0.041, r = 0.129). Physical dimension and relationship with the environment are more affected in pa-tients with low LVEF. Routine echocardiographic evaluation is essential in the global as-sessment of the HF patient and may suggest a low quality of life with impaired physical dimension.

Assessing patients' quality of life is frequently used in medical research. Patients di-agnosed with heart failure (HF) have reduced exercise tolerance and reduced quality of life due to reduced heart pump function. The objectives of the study are (i) to assess quality of life and comorbidities in HF patients; (ii) to compare quality of life in the physical and psychological do-mains according to drug treatment followed and (iii) to identify predictors of the two domains as-sessed. Methods. A cross-sectional study was conducted between February 2023 and May 2024. A total of 169 patients with HF were included and were distributed into two groups: the HF -S/V group (N=64) who received treatment with sacubitril/valsartan and the HF -CT group (N=105) received treatment with conventional therapy. Two questionnaires were used to assess patients: the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF) questionnaire and the Charlson Comorbidity Index (CCI). Results: The values determined for physical and psy-chological health were significantly lower for Group HF - S/V (51.391 ± 22.232 vs. 61.79 ± 20.04, p=0.002, respectively 59.203 ± 16.871 vs. 64.933 ± 17.448, p=0.038). Approximately 25% of all re-cruited patients distributed in the 2nd CCI category (CCI score 3-4) have an overall poor and moderately poor perception of quality of life vs. 35.5% of patients distributed in the 3rd CCI cate-gory (CCI ≤ 5); 55% of them belong to the HF - S/V group. A good perception of health status is held by 29 (17.16% of the HF group) of the patients distributed in the 2nd CCI category and 28 (16.56%) have a low and moderate perception. Conclusions: The values for the Physical health domain are moderately low, while the values obtained for the psychological domain show that this domain is less affected. Predictors identified for physical health and psychological well-being are patient age, weight, CCI.